By: ChinaBio® Today
March 28, 2013 at 09:32 AM EDT
SK Biopharma Partners with China Companies on Novel CNS Drug
SK Biopharmaceuticals of South Korea has formed a collaboration with two China companies to develop its novel treatment for depression and bipolar disorder. Together with SK Biopharma, Shanghai Medicilon has been working on the pre-clinical tests for the drug candidate, known as SKL-PSY. They have been joined by two subsidiaries of PKU International HealthCare. The collaboration expects to begin China clinical trials of SKL-PSY later this year. More details.... Share this with colleagues: // //
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here